Qx Therapeutics Inc. has been awarded SMALL BUSINESS INNOVATION RESEARCH PROG (SBIR) Phase 1 grants of $269,641 by the NIH National Heart, Lung, and Blood Institute (NHLBI). This award will support the research and development work for lead project QXT-101 for the treatment of Acute Lung Injury (ALI) and Acute Respiratory Distress Symptoms (ARDS).
“We are very excited and feel privilege to have received this award by the NIH. This show the important of this project for the health of the people in America and the recognition of the direction we are taking to advance this drug candidate forward by the NIH.”